L
Laguna Bio
Develops immunotherapies that activate the innate immune system to combat solid tumors
About Laguna Bio
Laguna Bio focuses on developing advanced immunotherapy solutions using allogeneic T cells. These cells are expanded ex vivo with IL2, IL15, and zoledronate, which are then paired with bispecific antibodies to harness the immune system's potential for therapeutic purposes. The company addresses safety concerns from previous trials by ensuring that Laguna Listeria cannot grow extracellularly. Laguna Bio operates in the biotechnology sector, targeting healthcare providers and research institutions seeking cutting-edge immunotherapy treatments. The business model likely involves partnerships with medical facilities and research organizations, generating revenue through licensing agreements and collaborative research projects. Keywords: immunotherapy, allogeneic T cells, IL2, IL15, zoledronate, bispecific antibodies, immune response, biotechnology, healthcare, research, licensing.
Source: Dealroom company dataAt a glance
- Founded
- 2022
- Headquarters
- San Francisco, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- CSChris Shu
SOSV- PVPacific 8 Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Laguna Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Laguna Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.